Skip to main content
CORESTEMCHEMON Inc. logo

CORESTEMCHEMON Inc. — Investor Relations & Filings

Ticker · 166480 ISIN · KR7166480004 KO Professional, scientific and technical activities
Open in API
Filings indexed 274 across all filing types
Latest filing 2026-04-01 Major Shareholding Noti…
Country KR South Korea
Listing KO 166480

About CORESTEMCHEMON Inc.

https://www.corestemchemon.com/eng/main…

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a "주식등의 대량보유상황보고서(일반)" filed under the Capital Markets Act to disclose changes in large shareholdings by a major shareholder and related parties. It details share counts, ownership percentages, thresholds, reasons for change, and contractual arrangements, which aligns with a Major Shareholding Notification. Thus, the correct code is MRQ.
2026-04-01 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory disclosure (to the Financial Supervisory Service/KRX) concerning the grant (and correction) of stock options (“주식매수선택권 부여에 관한 신고”). It is not an annual or quarterly report, earnings release, or management change notice. Instead, it announces the issuance of share‐linked rights (a future share issue) and corrections thereto. This fits the “Share Issue/Capital Change” category (SHA), which covers announcements of new share issues or other capital structure changes.
2026-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an announcement of the resolutions and detailed voting results from the company’s Annual General Meeting held on 27 March 2026, listing each proposal, whether it was passed, and voting percentages. This fits the definition for “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korean financial authorities. It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and specific financial ratios (capital impairment, operating loss) for the fiscal year. While it contains financial data, it is a standardized regulatory disclosure announcement regarding the completion and submission of the audit report, rather than the full annual report (10-K) or a standalone audit report document (AR). Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-19 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Independent Auditor's Report' (감사보고서) for Corestemchemon Co., Ltd. It includes the auditor's opinion, key audit matters, and the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. This is a formal, full-year financial audit report, not an announcement or a summary, fitting the definition of an Audit Report (AR). FY 2025
2026-03-19 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for Holding a General Meeting on a Concentrated Date'. It explains why the company is holding its shareholder meeting on a date designated by the KOSDAQ Association as a 'concentrated date' (high volume of meetings). This is a specific regulatory disclosure requirement in the Korean market and does not fit into categories like AGM-R (presentation materials) or PSI (proxy solicitation), but rather serves as a general regulatory notification.
2026-03-04 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.